We asked Dr. James Hutchinson, transplant immunologist at the University Hospital in Regensburg, Germany, what he thinks about recombinant antibodies in flow cytometry
Researchers and opinion leaders have considered a number of potential solutions to the so-called antibody-related reproducibility crisis. One way to make flow cytometry more reproducible is to transition from traditional monoclonal antibodies to recombinant ones. But what makes recombinant antibodies better than conventional hybridoma-derived antibodies?
REAfinity Antibodies are recombinantly generated antibodies that provide superior lot-to-lot consistency and purity, as compared to mouse or rat monoclonal antibodies. They have been engineered to lack background binding even without FcR blocking. In addition, they all have the same human IgG1 isotype, eliminating the need to include multiple isotype controls during flow analysis.
Find out more at [ Ссылка ]
Miltenyi Biotec is a global provider of products and services that advance biomedical research and cellular therapy. Our innovative tools support research at every level, from basic research to translational research to clinical application. This integrated portfolio enables scientists and clinicians to obtain, analyze, and utilize the cell. Our technologies cover techniques of sample preparation, cell isolation, cell sorting, flow cytometry, cell culture, molecular analysis, and preclinical imaging. Our more than 25 years of expertise spans research areas including immunology, stem cell biology, neuroscience, and cancer, and clinical research areas like hematology, graft engineering, and apheresis. In our commitment to the scientific community, we also offer comprehensive scientific support, consultation, and expert training. Today, Miltenyi Biotec has more than 2,500 employees in 25 countries – all dedicated to helping researchers and clinicians around the world make a greater impact on science and health.
Transplant immunologist Dr. James Hutchinson has switched from traditional hybridoma-derived antibodies to recombinant ones. Watch the interview to find out why!
